The global Dura Substitute market gathered revenue around USD 176.1 Million in 2021 and market is set to grow USD 328.1 Million by the end of 2030 and is estimated to expand at a modest CAGR of 5.2% during the prediction period 2022 to 2030.
Growth Factors:
Prevalence of CNS tumors caused by neurological disorders is increasing. Chiari malformation and spinal cord tumor-related neurosurgery procedures that necessitate dural grafts have become more common.
Rise in prevalence of neurological diseases requires neurosurgical treatments as well as duraplasty for effective and safe treatment outcomes. In 2018, more than half of all dural substitutes were utilized in cranial and spine tumor surgeries. This is expected to continue in the near future. Therefore, rise in prevalence of neurosurgical diseases leads to an increase in cranial and spinal duraplasty procedures, which in turn is anticipated to boost the demand for dura substitutes.
Researchers have attempted to employ various synthetic polymers to make dural substitutes in order to minimize the spread of diseases caused by the use of allogeneic or xenogeneic materials, increase clinical effectiveness, and reduce costs
Synthetic macromolecular materials, in comparison to collagen-based dura substitutes, lack the biological functions of stimulating cell migration and boosting the production of related cytokines. Scientists have attempted to create dura substitutes by incorporating gelatin or silk fibroin into the polymer. This approach not only assures the bionic structure of the dural replacement, but also enhances the material's biological function and surface properties, improving its repair effects.
Therefore, benefits such as enhanced clinical effectiveness, increased safety, and minimal adverse effects associated with synthetic dura substitutes are anticipated to fuel the growth of the dura substitute market
Report Scope of the Dura Substitute Market
Report Coverage |
Details |
Market Size |
US$ 328.1 Million by 2030 |
Growth Rate |
CAGR of 5.2% from 2022 to 2030 |
Largest Market |
North America |
Fastest Growing Market |
Asia Pacific |
Base Year |
2021 |
Forecast Period |
2022 to 2030 |
Segments Covered |
Material, Application, End-user and Region, |
Companies Mentioned |
Cook Medical LLC, B. Braun Melsungen AG, Integra LifeSciences, Cousin Surgery, W. L. Gore & Associates, Inc., Biosynth Lifesciences, Acera Surgical, Inc., Medprin, Medtronic, Stryker, DePuy Synthes, Gunze Limited, Baxter, Bennett Health, Inc., RTI Surgical, Natus Medical Incorporated |
Dura Substitute Market: Overview
Dural substitute is a type of medical device used in surgeries to repair dura mater, the outermost layer that covers and protects the brain. Animal collagen or nanofibers woven together with an elastic material to form a soft tamponade can also be used to create a dural substitute.
Dural substitutes are required to prevent CSF leaks and to allow dural openings to heal after surgery. Dural substitutes can be biological or synthetic, harvested from animals or human cadavers, and used as an onlay or suturable grafts. The key advantage of using a dural substitute is that it is similar to the patient's dura and can absorb and integrate into the host tissue.
Rise in the number of road accidents and sports injuries, which increases the need of neurosurgery, is the major factor boosting market growth. However, product recalls is likely to hamper market growth.
Government Funding in Regenerative Medicine Contributing to Market Growth
Government funding for the treatment of various diseases is increasing globally due to the formulation and adoption of supporting legislation & policies. Such trends are contributing to expansion of the regenerative medicine sector in the dura substitute market.
Healthcare companies are drawing significant expenditure in regenerative medicines such as the establishment of centers of excellence, manufacturing infrastructure, and research networks, among others. The NIH (National Institutes of Health) Common Fund facilitated the establishment of the NIH Center for Regenerative Medicine in 2010 with the purpose of serving as a national resource for stem cell sciences. Such developments are helping to accelerate the development of novel medical applications and cell-based therapeutics.
Transition from Animal Tissue-derived Materials to Synthetic Materials Aiding Market Growth
Dural repair materials are transitioning from animal tissue-derived materials to synthetic materials as well as from inert to absorbable properties. Such findings are bringing a significant change in the global dura substitute market.
Biomimetic patch is a new dural repair product that provides functional properties similar to alternate therapies. This patch has a 3 dimensional (3D) non-woven microfiber structure that is both mechanically strong and biocompatible. The animal investigation revealed that the biomimetic patch and commercially synthesized material groups demonstrated new subdural regeneration after 90 days, with low inflammatory response and minimal to no adhesion development at each stage. It has been found that the biomimetic structure and proper rate of degradation of the new absorbable dura replacement can lead significant regeneration of the dura mater.
Market Segmentation: Dura Substitute Market
In terms of material, the global dura substitute market has been bifurcated into biological graft and synthetic graft. The biological graft segment has been split into autografts, allografts, and xenografts. The synthetic segment has been segregated into polytetrafluoroethylene and others.
Based on application, the global dura substitute market has been classified into neurosurgery and spinal surgery
In terms of end-user, the global dura substitute market has been divided into hospitals, ambulatory surgical centers, and others
Each of the segments has been analyzed in detail for market trends, recent trends, and developments, drivers, restraints, opportunities, and useful insights. The dura substitute market report provides current and expected revenue (US$ Mn) for each of these segments from 2022 to 2030, considering 2021 as the base year. The compound annual growth rate (percentage CAGR) has been provided for each segment and market from 2022 to 2030 along with market size estimations.
Regional Overview: Dura Substitute Market
In terms of region, the global dura substitute market has been segmented into North America, Europe, Latin America, Asia Pacific, and Middle East & Africa
North America dominated the global dura substitute market in 2021, accounting for 41.9% share. Developed healthcare infrastructure and presence of patient-specific healthcare systems fuel the growth of the dura substitute market in North America.
The U.S. dominated the market in North America due to rapid adoption of new technologies for soft tissue repair, presence of key players, and higher penetration of research activities across the country
Moreover, growing burden of neurosurgical diseases is leading to increase in cranial and spinal duraplasty, which, in turn, is likely to boost the demand for dura substitute in the region
Some of the prominent players in the Dura Substitute Market include:
Segments Covered in the Report
This research report offers market revenue, sales volume, production assessment and prognoses by classifying it on the basis of various aspects. Further, this research study investigates market size, production, consumption and its development trends at global, regional, and country level for the period of 2017 to 2030 and covers subsequent region in its scope:
By Geography
North America
Europe
Asia Pacific
Latin America
Middle East & Africa (MEA)
Key Points Covered in Dura Substitute Market Study:
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Dura Substitute Market
4. Market Overview
4.1. Introduction
4.1.1. Material Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Dura Substitute Market Analysis and Forecast, 2017–2030
4.4.1. Market Revenue Projections (US$ Mn)
5. Key Insights
5.1. Technological Advancements
5.2. Key Industry Events (mergers, acquisitions, partnerships, collaborations, etc.)
5.3. Pricing Analysis
5.4. Product /Brand Analysis, by Application
5.5. COVID-19 Pandemic Impact on Industry (value chain and short / mid / long term impact)
6. Global Dura Substitute Market Analysis and Forecast, by Material
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast, by Material, 2017–2030
6.3.1. Biological Grafts
6.3.1.1. Autografts
6.3.1.2. Allografts
6.3.1.3. Xenografts
6.3.1.3.1. Collagen
6.3.1.3.2. Decellularized Pericardium
6.3.1.3.3. Small Intestine Submucosa
6.3.2. Synthetic
6.3.2.1. Polytetrafluoroethylene (PTFE)
6.3.2.2. Others
6.4. Market Attractiveness Analysis, by Material
7. Global Dura Substitute Market Analysis and Forecast, by Application
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast, by Application, 2017–2030
7.3.1. Neurosurgery
7.3.2. Spinal Surgery
7.4. Market Attractiveness Analysis, by Application
8. Global Dura Substitute Market Analysis and Forecast, by End-user
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Market Value Forecast, by End-user, 2017–2030
8.3.1. Hospitals
8.3.2. Ambulatory Surgical Centers
8.3.3. Others
8.4. Market Attractiveness Analysis, by End-user
9. Global Dura Substitute Market Analysis and Forecast, by Region
9.1. Key Findings
9.2. Market Value Forecast, by Region
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
9.3. Market Attractiveness Analysis, by Region
10. North America Dura Substitute Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value Forecast, by Material, 2017–2030
10.2.1. Biological Grafts
10.2.1.1. Autografts
10.2.1.2. Allografts
10.2.1.3. Xenografts
10.2.1.3.1. Collagen
10.2.1.3.2. Decellularized Pericardium
10.2.1.3.3. Small Intestine Submucosa
10.2.2. Synthetic
10.2.2.1. Polytetrafluoroethylene (PTFE)
10.2.2.2. Others
10.3. Market Value Forecast, by Application, 2017–2030
10.3.1. Neurosurgery
10.3.2. Spinal Surgery
10.4. Market Value Forecast, by End-user, 2017–2030
10.4.1. Hospitals
10.4.2. Ambulatory Surgical Centers
10.4.3. Others
10.5. Market Value Forecast, by Country, 2017–2030
10.5.1. U.S.
10.5.2. Canada
10.6. Market Attractiveness Analysis
10.6.1. By Material
10.6.2. By Application
10.6.3. By End-user
10.6.4. By Country
11. U.S Dura Substitute Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Material, 2017–2030
11.2.1. Biological Grafts
11.2.2. Synthetic
11.3. Market Value Forecast, by Application, 2017–2030
11.3.1. Neurosurgery
11.3.2. Spinal Surgery
11.4. Market Attractiveness Analysis
11.4.1. By Material
11.4.2. By Application
12. Canada Dura Substitute Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Material, 2017–2030
12.2.1. Biological Grafts
12.2.2. Synthetic
12.3. Market Value Forecast, by Application, 2017–2030
12.3.1. Neurosurgery
12.3.2. Spinal Surgery
12.4. Market Attractiveness Analysis
12.4.1. By Material
12.4.2. By Application
13. Europe Dura Substitute Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Material, 2017–2030
13.2.1. Biological Grafts
13.2.1.1. Autografts
13.2.1.2. Allografts
13.2.1.3. Xenografts
13.2.1.3.1. Collagen
13.2.1.3.2. Decellularized Pericardium
13.2.1.3.3. Small Intestine Submucosa
13.2.2. Synthetic
13.2.2.1. Polytetrafluoroethylene (PTFE)
13.2.2.2. Others
13.3. Market Value Forecast, by Application, 2017–2030
13.3.1. Neurosurgery
13.3.2. Spinal Surgery
13.4. Market Value Forecast, by End-user, 2017–2030
13.4.1. Hospitals
13.4.2. Ambulatory Surgical Centers
13.4.3. Others
13.5. Market Value Forecast, by Country/Sub-region, 2017–2030
13.5.1. Germany
13.5.2. U.K
13.5.3. France
13.5.4. Italy
13.5.5. Spain
13.5.6. Denmark
13.5.7. Sweden
13.5.8. Finland
13.5.9. Iceland
13.5.10. Norway
13.5.11. Rest of Europe
13.6. Market Attractiveness Analysis
13.6.1. By Material
13.6.2. By Application
13.6.3. By End-user
13.6.4. By Country/Sub-region
14. Germany Dura Substitute Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Material, 2017–2030
14.2.1. Biological Grafts
14.2.2. Synthetic
14.3. Market Value Forecast, by Application, 2017–2030
14.3.1. Neurosurgery
14.3.2. Spinal Surgery
14.4. Market Attractiveness Analysis
14.4.1. By Material
14.4.2. By Application
15. U.K Dura Substitute Market Analysis and Forecast
15.1. Introduction
15.1.1. Key Findings
15.2. Market Value Forecast, by Material, 2017–2030
15.2.1. Biological Grafts
15.2.2. Synthetic
15.3. Market Value Forecast, by Application, 2017–2030
15.3.1. Neurosurgery
15.3.2. Spinal Surgery
15.4. Market Attractiveness Analysis
15.4.1. By Material
15.4.2. By Application
16. France Dura Substitute Market Analysis and Forecast
16.1. Introduction
16.1.1. Key Findings
16.2. Market Value Forecast, by Material, 2017–2030
16.2.1. Biological Grafts
16.2.2. Synthetic
16.3. Market Value Forecast, by Application, 2017–2030
16.3.1. Neurosurgery
16.3.2. Spinal Surgery
16.4. Market Attractiveness Analysis
16.4.1. By Material
16.4.2. By Application
17. Italy Dura Substitute Market Analysis and Forecast
17.1. Introduction
17.1.1. Key Findings
17.2. Market Value Forecast, by Material, 2017–2030
17.2.1. Biological Grafts
17.2.2. Synthetic
17.3. Market Value Forecast, by Application, 2017–2030
17.3.1. Neurosurgery
17.3.2. Spinal Surgery
17.4. Market Attractiveness Analysis
17.4.1. By Material
18. Competition Landscape
18.1. Market Player - Competition Matrix (by tier and size of companies)
18.2. Market Share Analysis, by Company, 2020
18.3. Company Profiles
18.3.1. Cook Medical LLC
18.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
18.3.1.2. Product Portfolio
18.3.1.3. SWOT Analysis
18.3.1.4. Strategic Overview
18.3.2. B. Braun Melsungen AG
18.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
18.3.2.2. Product Portfolio
18.3.2.3. SWOT Analysis
18.3.2.4. Strategic Overview
18.3.3. Integra LifeSciences
18.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
18.3.3.2. Product Portfolio
18.3.3.3. SWOT Analysis
18.3.3.4. Strategic Overview
18.3.4. Cousin Surgery
18.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
18.3.4.2. Product Portfolio
18.3.4.3. SWOT Analysis
18.3.4.4. Strategic Overview
18.3.5. W. L. Gore & Associates, Inc.
18.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
18.3.5.2. Product Portfolio
18.3.5.3. SWOT Analysis
18.3.5.4. Strategic Overview
18.3.6. Biosynth Lifesciences
18.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
18.3.6.2. Product Portfolio
18.3.6.3. SWOT Analysis
18.3.6.4. Strategic Overview
18.3.7. Acera Surgical, Inc.
18.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
18.3.7.2. Product Portfolio
18.3.7.3. SWOT Analysis
18.3.7.4. Strategic Overview
18.3.8. Medprin
18.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
18.3.8.2. Product Portfolio
18.3.8.3. SWOT Analysis
18.3.8.4. Strategic Overview
18.3.9. Medtronic
18.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
18.3.9.2. Product Portfolio
18.3.9.3. SWOT Analysis
18.3.9.4. Strategic Overview
18.3.10. Stryker
18.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
18.3.10.2. Product Portfolio
18.3.10.3. SWOT Analysis
18.3.10.4. Strategic Overview
18.3.11. DePuy Synthes
18.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
18.3.11.2. Product Portfolio
18.3.11.3. SWOT Analysis
18.3.11.4. Strategic Overview
18.3.12. Gunze Limited
18.3.12.1. Company Overview (HQ, Business Segments, Employee Strength)
18.3.12.2. Product Portfolio
18.3.12.3. SWOT Analysis
18.3.12.4. Strategic Overview
18.3.13. Baxter
18.3.13.1. Company Overview (HQ, Business Segments, Employee Strength)
18.3.13.2. Product Portfolio
18.3.13.3. SWOT Analysis
18.3.13.4. Strategic Overview
18.3.14. Bennett Health, Inc.
18.3.14.1. Company Overview (HQ, Business Segments, Employee Strength)
18.3.14.2. Product Portfolio
18.3.14.3. SWOT Analysis
18.3.14.4. Strategic Overview
18.3.15. RTI Surgical
18.3.15.1. Company Overview (HQ, Business Segments, Employee Strength)
18.3.15.2. Product Portfolio
18.3.15.3. SWOT Analysis
18.3.15.4. Strategic Overview
18.3.16. Natus Medical Incorporated
18.3.16.1. Company Overview (HQ, Business Segments, Employee Strength)
18.3.16.2. Product Portfolio
18.3.16.3. SWOT Analysis
18.3.16.4. Strategic Overview